Three pediatricians explore the secondary thromboembolic diseases that children are living long enough to be susceptible to now that many previously primary lethal disorders have become treatable to various degrees. The 33 chapters discuss the currently available therapies and present guidelines for treatment. Originally published as Thromboembolic complications during infancy and childhood, the third edition adds chapters on interpreting coagulation tests and giving immunizations. Annotation ©2007 Book News, Inc., Portland, OR (booknews.com)
Preface |
|
v | |
Introduction |
|
vii | |
|
Section 1: Useful Information |
|
|
|
|
3 | (28) |
|
|
31 | (7) |
|
Common Cardiac Surgical Procedures |
|
|
38 | (5) |
|
Anticoagulant Generic and Trade Names |
|
|
43 | (3) |
|
Section 2: Diagnosis Of Thromboembolic Disease In Children |
|
|
|
Diagnosis of Noncerebral Venous Thrombosis |
|
|
46 | (8) |
|
Diagnosis of Noncerebral Arterial Thrombosis |
|
|
54 | (5) |
|
Diagnosis of Cerebral Sinovenous Thrombosis |
|
|
59 | (5) |
|
Diagnosis of Arterial Ischemic Stroke |
|
|
64 | (6) |
|
Diagnosis of Thrombophilic Conditions |
|
|
70 | (7) |
|
Section 3: Antithrombotic Therapy In Children |
|
|
|
|
77 | (8) |
|
Low-Molecular-Weight Heparin Therapy |
|
|
85 | (8) |
|
|
93 | (3) |
|
Management of Heparin-Induced Thrombocytopenia |
|
|
96 | (8) |
|
Vitamin K Antagonists: Warfarin and Acenocoumarol Therapy |
|
|
104 | (12) |
|
|
116 | (6) |
|
Elective Reversal of Warfarin Therapy |
|
|
122 | (4) |
|
Systemic Thrombolytic Therapy |
|
|
126 | (9) |
|
|
135 | (4) |
|
Surgical Interventions for Thromboembolic Disease |
|
|
139 | (2) |
|
Newer Anticoagulant Drugs |
|
|
141 | (5) |
|
Section 4: Guidelines For Antithrombotic Therapy In Specific Situations |
|
|
|
Management of Blocked Central Venous Lines |
|
|
146 | (5) |
|
Treatment of Deep Venous Thrombosis |
|
|
151 | (7) |
|
Management of Post-thrombotic Syndrome |
|
|
158 | (2) |
|
Anticoagulation Therapy for Specific Cardiac Conditions and Surgery of Childhood |
|
|
160 | (4) |
|
Anticoagulation Therapy for Artificial Heart Valve |
|
|
164 | (3) |
|
Treatment of Coronary Artery Disease in Children |
|
|
167 | (3) |
|
Neonatal Purpura Fulminans |
|
|
170 | (3) |
|
Renal Vein/Portal Vein Thrombosis |
|
|
173 | (3) |
|
Management of Arterial Thrombosis |
|
|
176 | (11) |
|
Section 5: Guidelines For Antithrombotic Therapy In Stroke |
|
|
|
Acute Arterial Ischemic Stroke |
|
|
187 | (8) |
|
|
195 | (5) |
|
Stroke in Sickle Cell Disease |
|
|
200 | (3) |
|
Section 6: Guidelines For Procedural Interventions In Children On Anticoagulant Therapy |
|
|
|
|
203 | (3) |
Appendix Useful Web Sites, References, and Contacts |
|
206 | (4) |
Index |
|
210 | |
Paul Monagle, MBBS, MD, MSc, FRACP, FRCPA, FCCP Professor, Chair, Head Department of Pathology University of Melbourne Director, Haematology Department of Pediatrics Royal Children's Hospital Melbourne, Australia Anthony K.C. Chan, MBBS, FRCPC Career Investigator, Heart and Stroke Foundation of Canada Medical Director, Coagulation Laboratory The Hospital for Sick Children, Toronto, Canada Professor of Pediatrics McMaster University, Hamilton, Canada M Patricia Massicotte, MD, MHSc Peter Olley Chair in Pediatric Thrombosis Professor, Pediatrics University of Alberta Edmonton, Canada Gabrielle deVeber, MD, FRCPC, MHSc Associate Professor, Department of Pediatrics University of Toronto Scientist, Population Health Sciences The Hospital for Sick Children Research Institute Director, Children's Stroke Program, Division of Neurology The Hospital for Sick Children Toronto, Canada